Almirall Logo
  • Our Purpose
    • Our Purpose
  • Your Health
    • Your skin
      • Skin Conditions
        • Psoriasis
        • Actinic Keratosis
        • Atopic Dermatitis
        • Acne
        • Rare skin diseases
        • Onychomycosis
        • Alopecia Areata
        • Skin Cancer
        • Vitiligo
        • Hidradenitis suppurativa
      • Types of Skin
      • About Skin
      • Sanctuary Salon
        • Patients
    • More than skin
      • Spasticity In MS
      • Chronic Pain
    • Commitment to patients
    • Report a side effect
    oscar-psoriasis-megamenu.jpg

    Living with psoriasis

    You worry about…

    • Psoriasis
    • Actinic keratosis
    • Atopic dermatitis
    • Acne
    • Onychomycosis
    View all skin conditions

    Take care of your skin

    • Types of skin
    • About skin
    • Sanctuary Salon

    More than skin…

    • Spasticity in MS
    • Chronic pain
    • Our commitment to patient associations
    • Report a side effect
  • Our Expertise
    • Research & Development
      • Pipeline
      • Clinical Trials
      • R&D Collaboration
    • Our disease focus
    • Our Products
    • Partnering
  • HC Professional
  • Sustainability
    • Planet
    • Patients
    • People
    • Partners
    • Principles
    • Transparency
  • Almirall 80 years Almirall 80 years

    • Select your Almirall

    • France
    • Germany
    • Italy
    • Netherlands
    • Poland
    • Spain
    • Spain (Català)
    • Austria
    • Switzerland
    • United Kingdom
    • United States of America
    • Czechia
    • Slovakia
    • Nordic Countries
  • Media
    • About Us
    • Newsroom
    • Media Resources
    • Media Contact
    • Annual Reports
  • Investors
    • Information
      • Share Performance
      • Share and capital structure
      • Shareholdings
      • Takeover bids
      • Dividends
      • Share issues
      • Debt issues
      • Analyst coverage
    • Financial Data
      • Financial results and accounts
      • Public Periodic Information
      • Factsheet
      • Corporate presentations
    • Annual Report
    • CNMV Communications
      • Insider Information
      • Other Relevant Information
      • Significants Events up to 8th February 2020
    • News
    • Calendar
    • Corporate Governance
      • Corporate Governance Presentation
      • Shareholders Annual General Meeting
      • Board of Directors
      • Corporate Policies
      • Board Commissions
      • Management Board
      • Corporate Governance Annual reports and Remuneration of Directors reports
      • Agreements between significant shareholders
      • Average period of payments to suppliers
      • Information Security
  • Careers

View all results

  • Information
    • Share Performance
    • Share and capital structure
    • Shareholdings
    • Takeover bids
    • Dividends
    • Share issues
    • Debt issues
    • Analyst coverage
  • Financial Data
    • Financial results and accounts
    • Public Periodic Information
    • Factsheet
    • Corporate presentations
  • Annual Report
  • CNMV Communications
    • Insider Information
    • Other Relevant Information
    • Significants Events up to 8th February 2020
  • News
  • Calendar
  • Corporate Governance
    • Corporate Governance Presentation
    • Shareholders Annual General Meeting
    • Board of Directors
    • Corporate Policies
    • Board Commissions
    • Management Board
    • Corporate Governance Annual reports and Remuneration of Directors reports
    • Agreements between significant shareholders
    • Average period of payments to suppliers
    • Information Security
  • Investors
  • Financial Data
  • Corporate presentations

Corporate presentations

Here, we provide corporate presentations submitted to the analyst and investors community.

  • 43rd Annual J.P. Morgan Healthcare Conference 2025 (audio) MP3 (15.4MB)
  • 43rd Annual J.P. Morgan Healthcare Conference 2025 PDF (1.7MB)
  • Presentation of 16 weeks data for Lebrikizumab ADvocate 1 & 2 Phase 3 studies PDF (1.9MB)
  • Presentation of 16 weeks data for Lebrikizumab ADvocate 1 & 2 Phase 3 studies (audio) MP3 (19.7MB)
Logo footer
footer claim

QUICK LINKS

  • Our purpose
  • Your health
  • Our expertise
  • Sustainability
  • Almirall 80 years
  • Stories
  • Corporate Governance

FIND YOUR ALMIRALL

  • Media
  • Investors
  • Careers
  • Partnering
  • Suppliers
  • HC Professionals

KEEP IN TOUCH

  • Contact us
  • Report a side effect
  • Subscribe to update

FOLLOW US

Find out the latest about Almirall at our social networks

  • Linkedin
  • Youtube
  • Instagram

Speak UP!

  • Speak Up channel
  • Whistleblowing Policy

Copyright 2024 © Almirall, S.A All rights reserved

  • Privacy Policy
  • Terms of Service
  • Cookies
  • Privacy Policy HCPs
  • Site map

We are going to take you to a different platform

This platform is safe as takes part of Almirall ecosystem

Cancel

Accept

You are about to leave www.almirall.com

Specific policies may apply to the site you are visiting; all interaction with that site is at your own risk.

Cancel

Accept

The content you are about to see is restricted to media professional use

Please let us know if you are a professional to continue.

Cancel

I'm a media professional

Your browser is not compatible with our website.

The version of Internet Explorer you are using is outdated. To have a complete user experience in almirall.com, we recommend you to update your browser or enter from the latest versions of Edge, Chrome, Safari, Opera or Firefox.

OK

The content you are about to view is exclusively targeted to healthcare professionals empowered to prescribe or dispense medications.

Please, so you can continue, confirm us that you are a healthcare professional empowered to prescribe or dispense medications and you have the needed training to correctly interpret the information contained in this section.

No

Yes